AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31902327 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 31902327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 28255654 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt drink with oligofructose (20% reduced sugars)
Number of subjects: 42
Study 28255654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit jelly with inulin (30% less sugars)
Number of subjects: 42
Study 28255654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (yogurt with oligofructose and fruit jelly with inulin)
Number of subjects: 42
Study 27048670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C/E complex supplementation (100 IU of vitamin E + 500 mg of vitamin C) twice per day during radiotherapy
Number of subjects: 45
Study 27048670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 27048670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C/E complex supplementation
Number of subjects: 45
Study 27048670 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C/E complex supplementation and Placebo
Number of subjects: 45
Study 26298797 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (800mg EGCG daily)
Number of subjects: 23
Study 26298797 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 23
Study 26298797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24096631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (2 weeks)
Number of subjects: 597
Study 24096631 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (8 weeks)
Number of subjects: 597
Study 20679159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedialyte
Number of subjects: 66
Study 20679159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Electrolyte
Number of subjects: 66
Study 20679159 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfalyte
Number of subjects: 66
Study 20679159 — intervention group
Group type: COMPARATOR
Intervention: Enfalyte vs Pediatric Electrolyte
Number of subjects: 66
Study 20679159 — intervention group
Group type: COMPARATOR
Intervention: Enfalyte vs Pedialyte
Number of subjects: 66
Study 20679159 — intervention group
Group type: COMPARATOR
Intervention: Best-tasting solution
Number of subjects: 66
Study 18782781 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 88
Study 18782781 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus gentamicin
Number of subjects: 88
Study 17357307 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis solutions with low content of glucose degradation products
Number of subjects: 0
Study 17357307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid‐based, icodextrin‐based or glycerol‐based dialysis solution
Number of subjects: 0
Study 17357307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate or pyruvate as a buffer
Number of subjects: 0
Study 17357307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drugs
Number of subjects: 0
Study 17357307 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques to decrease infection rate
Number of subjects: 0
Study 12661776 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) for 2 years
Number of subjects: 36
Study 10719007 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 10 days
Number of subjects: 25
Study 10719007 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg bd for 10 days
Number of subjects: 25
Study 10719007 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin
Number of subjects: 25
Study 8957979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (racemic)
Number of subjects: 0
Study 8957979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (S+)
Number of subjects: 0
Study 8957979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1416684 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for diagnosis and management of acute appendicitis
Number of subjects: 58
Study 1416684 — intervention group
Group type: COMPARATOR
Intervention: Standard appendicectomy procedure
Number of subjects: 58
Study 3776447 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 5 vol% in 70% nitrous oxide in oxygen via a face mask
Number of subjects: 83
Study 3776447 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg/kg followed by suxamethonium 1.5 mg/kg i.v.
Number of subjects: 83
Study 3776447 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane with suxamethonium 2 mg/kg
Number of subjects: 83
Study 30929823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg/day until disease progression or unacceptable toxicity
Number of subjects: 27
Study 30929823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg/day
Number of subjects: 27
Study 27841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater expression of intestinal cholesterol metabolism genes (NPC1L1, ABC‐G5, ABC‐G8, ABC‐A1, MTTP, SREBP‐2)
Number of subjects: 100
Study 27841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater expression of NPC1L1, ABC‐G8, and SREBP‐2
Number of subjects: 100
Study 27841945 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater expression of MTTP, ABC‐A1, and SREBP‐2
Number of subjects: 100
Study 26002728 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol for 6 weeks
Number of subjects: 50
Study 26002728 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 50
Study 23246855 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg d-amphetamine
Number of subjects: 12
Study 23246855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23246855 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study 21274547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of a venotonic drug (micronized purified flavonoid fraction, Daflon 1,000 mg × 3) for 20 days
Number of subjects: 81
Study 21274547 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment alone
Number of subjects: 81
Study 19846544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention plus n-3 fatty acid supplementation (6 g/d)
Number of subjects: 54
Study 19846544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 19846544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention plus n-3 fatty acid supplementation
Number of subjects: 54
Study 16895071 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate, 2.5 mg/day, daily
Number of subjects: 23
Study 16895071 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily
Number of subjects: 23
Study 14711555 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients with AA excess
Number of subjects: 30
Study 14711555 — intervention group
Group type: COMPARATOR
Intervention: PCOS patients without AA excess
Number of subjects: 30
Study 11854119 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program (diet, exercise, behavioral counseling)
Number of subjects: 56
Study 11854119 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 56
Study 9602595 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) 50 ml
Number of subjects: 60
Study 9602595 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine solution with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Number of subjects: 60
Study 9602595 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 2% lidocaine with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Number of subjects: 60
Study 9602595 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 8022633 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 8022633 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 8022633 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord injury
Number of subjects: 0
Study 8022633 — intervention group
Group type: EXPERIMENTAL
Intervention: NASCIS dose of methylprednisolone
Number of subjects: 0
Study 3046231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg, 4 times a day)
Number of subjects: 52
Study 3046231 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg, 4 times a day)
Number of subjects: 52
Study 31121022 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31121022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 28914681 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/Oxidized Regenerated Cellulose/Silver with Standard of Care (SOC)
Number of subjects: 49
Study 28914681 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) alone
Number of subjects: 49
Study 25567818 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE OUT intervention
Number of subjects: 57
Study 25567818 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 23704713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (DPP4 inhibitor) during OGTT
Number of subjects: 26
Study 23704713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DPP4i) during OGTT
Number of subjects: 26
Study 23704713 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycaemic i.v. glucose infusion (IIGI)
Number of subjects: 26
Study 23704713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 26
Study 23704713 — intervention group
Group type: COMPARATOR
Intervention: DPP4i in controls
Number of subjects: 26
Study 21292809 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss + physical activity (WL + PA)
Number of subjects: 288
Study 21292809 — intervention group
Group type: COMPARATOR
Intervention: Physical activity only (PA)
Number of subjects: 288
Study 21292809 — intervention group
Group type: COMPARATOR
Intervention: Successful aging (SA) health education program
Number of subjects: 288
Study 19138452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy in addition to standard medical therapy (prednisolone starting at 1 mg/kg)
Number of subjects: 57
Study 19138452 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (prednisolone starting at 1 mg/kg)
Number of subjects: 57
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 60 Gy in 30 fractions
Number of subjects: 154
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 74 Gy at 2 Gy/fraction
Number of subjects: 154
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose escalation
Number of subjects: 154
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving fraction of tumour cells after a radiation dose of 2 Gy (SF2)
Number of subjects: 154
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay to start radiotherapy
Number of subjects: 154
Study 16523808 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 154
Study 14718694 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B (1,000 units into each parotid gland and 250 units into each submandibular gland)
Number of subjects: 16
Study 14718694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11522564 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg elemental Zinc daily for 5 months
Number of subjects: 301
Study 11522564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9266735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (average of 25 days)
Number of subjects: 66
Study 9266735 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study 7507765 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg, p.o.)
Number of subjects: 28
Study 7507765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2906887 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine-120 mg pseudoephedrine hydrochloride combination
Number of subjects: 315
Study 2906887 — intervention group
Group type: COMPARATOR
Intervention: 120 mg pseudoephedrine hydrochloride (extended release)
Number of subjects: 315
Study 29632101 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain training (n=55)
Number of subjects: 113
Study 29632101 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=58)
Number of subjects: 113
Study 29632101 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 113
Study 28668627 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0g vigabatrin solution
Number of subjects: 0
Study 28668627 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0g vigabatrin solution
Number of subjects: 0
Study 28668627 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin
Number of subjects: 0
Study 28668627 — intervention group
Group type: COMPARATOR
Intervention: Placebo vigabatrin solution
Number of subjects: 0
Study 25904205 — intervention group
Group type: EXPERIMENTAL
Intervention: PPNa-DBS combined with levodopa treatment
Number of subjects: 6
Study 25904205 — intervention group
Group type: EXPERIMENTAL
Intervention: PPNa-DBS
Number of subjects: 6
Study 25904205 — intervention group
Group type: COMPARATOR
Intervention: Without PPNa-DBS
Number of subjects: 6
Study 23556334 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole suspension administered orally in the fasted state
Number of subjects: 0
Study 23556334 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole suspension administered orally with a high-fat meal
Number of subjects: 0
Study 20512484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group instructed to maintain gaze on each target until heel contact
Number of subjects: 16
Study 20512484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 18222126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total psychological symptom score
Number of subjects: 420
Study 18222126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea severity
Number of subjects: 420
Study 18222126 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain for >12 weeks
Number of subjects: 420
Study 18222126 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal distension
Number of subjects: 420
Study 18222126 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of bowel movements
Number of subjects: 420
Study 16452343 — intervention group
Group type: EXPERIMENTAL
Intervention: ProQuad
Number of subjects: 399
Study 16452343 — intervention group
Group type: COMPARATOR
Intervention: M-M-RII
Number of subjects: 399
Study 16452343 — intervention group
Group type: COMPARATOR
Intervention: M-M-RII and Varivax
Number of subjects: 399
Study 16452343 — intervention group
Group type: EXPERIMENTAL
Intervention: ProQuad and Varivax
Number of subjects: 399
Study 15459598 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA followed by stenting
Number of subjects: 86
Study 15459598 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 86
Study 11527475 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance/endurance plus basic enhanced programming
Number of subjects: 110
Study 11527475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi plus basic enhanced programming
Number of subjects: 110
Study 11527475 — intervention group
Group type: COMPARATOR
Intervention: Basic enhanced programming only (Control)
Number of subjects: 110
Study 9240291 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 88
Study 9240291 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study 8279351 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator
Number of subjects: 20
Study 8279351 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2423652 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP (CCNU, vinblastine, procarbazine, and prednisone)
Number of subjects: 113
Study 2423652 — intervention group
Group type: EXPERIMENTAL
Intervention: ABOS (bleomycin, vincristine, doxorubicin, and streptozotocin)
Number of subjects: 113
Study 2423652 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP/ABOS (alternating cycles of CVPP and ABOS)
Number of subjects: 113
Study 2423652 — intervention group
Group type: COMPARATOR
Intervention: CVPP, ABOS, CVPP/ABOS (all treatments)
Number of subjects: 113
Study 2423652 — intervention group
Group type: COMPARATOR
Intervention: Complete responders (all treatments)
Number of subjects: 113
Study 2423652 — intervention group
Group type: COMPARATOR
Intervention: Age under 40 years (prognostic factor)
Number of subjects: 113
Study 31732283 — intervention group
Group type: EXPERIMENTAL
Intervention: TACMI
Number of subjects: 35
Study 31732283 — intervention group
Group type: COMPARATOR
Intervention: Non-TACMI
Number of subjects: 35
Study 30423137 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-supervised neuromuscular training program (UPEx-NTP)
Number of subjects: 31
Study 30423137 — intervention group
Group type: COMPARATOR
Intervention: One-on-one usual physiotherapy care (UPC)
Number of subjects: 31
Study 30423137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (UPEx-NTP and UPC)
Number of subjects: 31
Study 27650174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic physiotherapy (PPT)
Number of subjects: 53
Study 27650174 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 53
Study 27650174 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths and difficulties questionnaire (SDQ)
Number of subjects: 53
Study 25503550 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAIN score derived from INTERACT2 (C-statistic, 0.73) based on factors such as baseline ICH volume, recurrent ICH, anticoagulation with warfarin, intraventricular extension, and time to baseline CT.
Number of subjects: 1310
Study 25503550 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAIN score used in INTERACT1 validation cohort.
Number of subjects: 1310
Study 23775875 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/SRL
Number of subjects: 293
Study 23775875 — intervention group
Group type: COMPARATOR
Intervention: MMF/CNI
Number of subjects: 293
Study 20400651 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg (first dose 200 mg) twice daily for 5 days
Number of subjects: 11
Study 19210652 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during unsupported arm exercise (UAE)
Number of subjects: 32
Study 19210652 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during ground walking
Number of subjects: 32
Study 19210652 — intervention group
Group type: COMPARATOR
Intervention: Exercise without NIV
Number of subjects: 32
Study 17482983 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach programme promoting screening for tuberculosis
Number of subjects: 44986
Study 17482983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 44986
Study 15260882 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg/day vitamin D
Number of subjects: 130
Study 15260882 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mcg/day vitamin D
Number of subjects: 130
Study 15260882 — intervention group
Group type: COMPARATOR
Intervention: Both doses of vitamin D
Number of subjects: 130
Study 11429371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 0
Study 11429371 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 0
Study 11429371 — intervention group
Group type: COMPARATOR
Intervention: Topical Anesthesia
Number of subjects: 0
Study 11429371 — intervention group
Group type: COMPARATOR
Intervention: Cuff Volume (10 mL or 30 mL)
Number of subjects: 0
Study 11429371 — intervention group
Group type: COMPARATOR
Intervention: LMA vs PLMA at 30 mL cuff volume
Number of subjects: 0
Study 9153526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory leg discomfort condition
Number of subjects: 19
Study 9153526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined periodic limb movement and sensory leg discomfort conditions
Number of subjects: 19
Study 9153526 — intervention group
Group type: COMPARATOR
Intervention: Voluntary imitation of periodic limb movements
Number of subjects: 19
Study 8249871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradually increasing amounts of lactose in milk until maximum lactose dose tolerated was determined.
Number of subjects: 25
Study 8249871 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hydrogen tests with the maximum dose of lactose tolerated.
Number of subjects: 25
Study 3436031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mixed grass‐maize pollen extract
Number of subjects: 40
Study 3436031 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study 31215406 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions and educational software intervention
Number of subjects: 176
Study 31215406 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 28650526 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (30 mg)
Number of subjects: 18
Study 28650526 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (30 mg)
Number of subjects: 18
Study 28650526 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (30 mg)
Number of subjects: 18
Study 28650526 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 18
Study 26077087 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical pharyngeal stimulation (EPS)
Number of subjects: 30
Study 26077087 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30